000132673212-312025Q2False135368359355xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxncr:programxncr:targetxbrli:purexncr:phasexncr:segment00013267322025-01-012025-06-3000013267322025-08-0100013267322025-06-3000013267322024-12-3100013267322025-04-012025-06-3000013267322024-04-012024-06-3000013267322024-01-012024-06-300001326732us-gaap:CommonStockMember2024-12-310001326732us-gaap:AdditionalPaidInCapitalMember2024-12-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001326732us-gaap:RetainedEarningsMember2024-12-310001326732us-gaap:NoncontrollingInterestMember2024-12-310001326732us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100013267322025-01-012025-03-310001326732us-gaap:CommonStockMember2025-01-012025-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001326732us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001326732us-gaap:RetainedEarningsMember2025-01-012025-03-310001326732us-gaap:CommonStockMember2025-03-310001326732us-gaap:AdditionalPaidInCapitalMember2025-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001326732us-gaap:RetainedEarningsMember2025-03-310001326732us-gaap:NoncontrollingInterestMember2025-03-3100013267322025-03-310001326732us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001326732us-gaap:CommonStockMember2025-04-012025-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001326732us-gaap:RetainedEarningsMember2025-04-012025-06-300001326732us-gaap:CommonStockMember2025-06-300001326732us-gaap:AdditionalPaidInCapitalMember2025-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001326732us-gaap:RetainedEarningsMember2025-06-300001326732us-gaap:NoncontrollingInterestMember2025-06-300001326732us-gaap:CommonStockMember2023-12-310001326732us-gaap:AdditionalPaidInCapitalMember2023-12-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001326732us-gaap:RetainedEarningsMember2023-12-310001326732us-gaap:NoncontrollingInterestMember2023-12-3100013267322023-12-310001326732us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100013267322024-01-012024-03-310001326732us-gaap:CommonStockMember2024-01-012024-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001326732us-gaap:RetainedEarningsMember2024-01-012024-03-310001326732us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001326732us-gaap:CommonStockMember2024-03-310001326732us-gaap:AdditionalPaidInCapitalMember2024-03-310001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001326732us-gaap:RetainedEarningsMember2024-03-310001326732us-gaap:NoncontrollingInterestMember2024-03-3100013267322024-03-310001326732us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001326732us-gaap:CommonStockMember2024-04-012024-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001326732us-gaap:RetainedEarningsMember2024-04-012024-06-300001326732us-gaap:NoncontrollingInterestMember2024-04-012024-06-300001326732us-gaap:CommonStockMember2024-06-300001326732us-gaap:AdditionalPaidInCapitalMember2024-06-300001326732us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001326732us-gaap:RetainedEarningsMember2024-06-300001326732us-gaap:NoncontrollingInterestMember2024-06-3000013267322024-06-300001326732xncr:AlexionPharmaceuticalsIncMember2025-04-012025-06-300001326732xncr:AlexionPharmaceuticalsIncMember2024-04-012024-06-300001326732xncr:AlexionPharmaceuticalsIncMember2025-01-012025-06-300001326732xncr:AlexionPharmaceuticalsIncMember2024-01-012024-06-300001326732xncr:MorphoSysIncyteMember2025-04-012025-06-300001326732xncr:MorphoSysIncyteMember2024-04-012024-06-300001326732xncr:MorphoSysIncyteMember2025-01-012025-06-300001326732xncr:MorphoSysIncyteMember2024-01-012024-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2025-04-012025-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-04-012024-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2025-01-012025-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Member2024-01-012024-06-300001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2025-04-012025-06-300001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2024-04-012024-06-300001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2025-01-012025-06-300001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2024-01-012024-06-300001326732xncr:VirBiotechnologyInc.Member2025-04-012025-06-300001326732xncr:VirBiotechnologyInc.Member2024-04-012024-06-300001326732xncr:VirBiotechnologyInc.Member2025-01-012025-06-300001326732xncr:VirBiotechnologyInc.Member2024-01-012024-06-300001326732xncr:ThirdPartyLicenseAgreementMember2025-04-012025-06-300001326732xncr:ThirdPartyLicenseAgreementMember2024-04-012024-06-300001326732xncr:ThirdPartyLicenseAgreementMember2025-01-012025-06-300001326732xncr:ThirdPartyLicenseAgreementMember2024-01-012024-06-300001326732us-gaap:LicenseMember2025-04-012025-06-300001326732us-gaap:LicenseMember2024-04-012024-06-300001326732us-gaap:LicenseMember2025-01-012025-06-300001326732us-gaap:LicenseMember2024-01-012024-06-300001326732xncr:MilestoneMember2025-04-012025-06-300001326732xncr:MilestoneMember2024-04-012024-06-300001326732xncr:MilestoneMember2025-01-012025-06-300001326732xncr:MilestoneMember2024-01-012024-06-300001326732us-gaap:RoyaltyMember2025-04-012025-06-300001326732us-gaap:RoyaltyMember2024-04-012024-06-300001326732us-gaap:RoyaltyMember2025-01-012025-06-300001326732us-gaap:RoyaltyMember2024-01-012024-06-300001326732xncr:AlexionPharmaceuticalsIncMemberxncr:OptionAndLicenseAgreementMember2013-01-012013-01-310001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2025-04-012025-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2024-04-012024-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2025-01-012025-06-300001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2024-01-012024-06-300001326732xncr:AlexionPharmaceuticalsIncMemberxncr:OptionAndLicenseAgreementMember2025-06-300001326732xncr:MorphoSysMemberxncr:CollaborationAndLicenseAgreementMember2025-02-012025-02-280001326732xncr:MorphoSysMemberxncr:CollaborationAndLicenseAgreementMember2025-06-012025-06-300001326732xncr:MorphoSysMemberxncr:CollaborationAndLicenseAgreementMember2025-06-300001326732xncr:OCMLifeSciencesPortfolioLPOMERSMemberxncr:MonjuviRoyaltySaleAgreementMember2025-01-012025-06-300001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2025-04-012025-06-300001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2024-04-012024-06-300001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2025-01-012025-06-300001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2024-01-012024-06-300001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2025-06-300001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Memberxncr:TechnologyLicenseAgreementMember2023-12-222023-12-220001326732xncr:ShanghaiMabgeekBiotechCo.Ltd.Memberxncr:TechnologyLicenseAgreementMember2023-12-220001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2021-10-012021-10-310001326732xncr:VegaTherapeuticsInc.Memberxncr:TechnologyLicenseAgreementMember2021-10-310001326732xncr:VirBiotechnologyInc.Memberxncr:PatentLicenseAgreementMember2019-01-012019-12-310001326732xncr:VirBiotechnologyInc.Memberxncr:PatentLicenseAgreementMember2025-04-012025-06-300001326732xncr:VirBiotechnologyInc.Memberxncr:PatentLicenseAgreementMember2025-06-300001326732xncr:ThirdPartyLicenseAgreementMemberxncr:PatentLicenseAgreementMember2024-05-012024-05-310001326732us-gaap:MoneyMarketFundsMember2025-06-300001326732us-gaap:CorporateDebtSecuritiesMember2025-06-300001326732us-gaap:USTreasuryAndGovernmentMember2025-06-300001326732us-gaap:CashEquivalentsMember2025-06-300001326732xncr:MarketableSecuritiesMember2025-06-300001326732us-gaap:MoneyMarketFundsMember2024-12-310001326732us-gaap:CorporateDebtSecuritiesMember2024-12-310001326732us-gaap:USTreasuryAndGovernmentMember2024-12-310001326732us-gaap:CashEquivalentsMember2024-12-310001326732xncr:MarketableSecuritiesMember2024-12-310001326732xncr:INmuneBioInc.Memberus-gaap:CommonStockMember2025-06-300001326732xncr:INmuneBioInc.Memberus-gaap:CommonStockMember2024-12-310001326732xncr:ViridianTherapeuticsInc.Memberus-gaap:CommonStockMember2025-06-300001326732xncr:ViridianTherapeuticsInc.Memberus-gaap:CommonStockMember2024-12-310001326732xncr:ZenasBioPharmaInc.Memberus-gaap:CommonStockMember2025-06-300001326732xncr:ZenasBioPharmaInc.Memberus-gaap:CommonStockMember2024-12-310001326732us-gaap:CommonStockMember2025-06-300001326732us-gaap:CommonStockMember2024-12-310001326732xncr:INmuneBioInc.Member2025-04-012025-06-300001326732xncr:INmuneBioInc.Memberus-gaap:SubsequentEventMember2025-07-012025-07-310001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001326732us-gaap:FairValueMeasurementsRecurringMember2025-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001326732us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001326732us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001326732us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001326732us-gaap:FairValueMeasurementsRecurringMember2024-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-12-310001326732us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-12-310001326732xncr:LabEquipmentMember2025-06-300001326732xncr:LabEquipmentMember2024-12-310001326732xncr:ComputersSoftwareAndEquipmentMember2025-06-300001326732xncr:ComputersSoftwareAndEquipmentMember2024-12-310001326732us-gaap:FurnitureAndFixturesMember2025-06-300001326732us-gaap:FurnitureAndFixturesMember2024-12-310001326732us-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-06-300001326732us-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-12-310001326732us-gaap:ConstructionInProgressMember2025-06-300001326732us-gaap:ConstructionInProgressMember2024-12-310001326732xncr:PatentsDefiniteLifeMember2025-06-300001326732xncr:PatentsDefiniteLifeMember2024-12-310001326732xncr:LicensesAndOtherIntangibleAssetsMember2025-06-300001326732xncr:LicensesAndOtherIntangibleAssetsMember2024-12-310001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2023-11-032023-11-030001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMembersrt:ScenarioForecastMember2023-07-012025-12-310001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMembersrt:ScenarioForecastMember2026-01-012028-12-310001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMembersrt:ScenarioForecastMember2029-01-012029-01-010001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2023-10-012023-12-310001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2023-11-032023-11-030001326732us-gaap:RoyaltyMemberxncr:CollaborationAndLicenseAgreementMemberxncr:MorphoSysMember2023-07-012023-07-010001326732us-gaap:RoyaltyMemberxncr:OptionAndLicenseAgreementMemberxncr:AlexionPharmaceuticalsIncMember2025-06-3000013267322024-01-012024-12-310001326732us-gaap:PreferredStockMember2025-06-300001326732us-gaap:PreferredStockMember2024-12-310001326732xncr:SVBSecuritiesLLCMemberxncr:SalesAgreementMember2023-02-272023-02-270001326732xncr:SalesAgreementMember2025-01-012025-06-300001326732us-gaap:NoteWarrantMember2024-09-122024-09-120001326732us-gaap:NoteWarrantMember2024-09-120001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2021-06-012021-06-300001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2022-08-010001326732srt:ScenarioForecastMemberxncr:PasadenaCAOfficeAndLaboratorySpaceMember2026-09-300001326732xncr:PasadenaCAOfficeAndLaboratorySpaceMember2022-08-310001326732us-gaap:LetterOfCreditMember2025-06-300001326732xncr:The2023PlanMember2023-06-140001326732xncr:The2023PlanMember2025-06-122025-06-120001326732xncr:The2023PlanMember2025-06-300001326732us-gaap:EmployeeStockMember2025-06-300001326732xncr:The2013PlanMember2025-06-300001326732xncr:The2013And2023PlansMember2025-06-300001326732xncr:The2013PlanMemberus-gaap:RestrictedStockUnitsRSUMember2025-06-300001326732xncr:The2023PlanMemberus-gaap:RestrictedStockUnitsRSUMember2025-06-300001326732xncr:The2013And2023PlansMemberus-gaap:RestrictedStockUnitsRSUMember2025-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2025-04-012025-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001326732us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012025-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001326732us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001326732us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001326732us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001326732us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001326732us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001326732us-gaap:EmployeeStockMember2025-04-012025-06-300001326732us-gaap:EmployeeStockMember2024-04-012024-06-300001326732us-gaap:EmployeeStockMember2025-01-012025-06-300001326732us-gaap:EmployeeStockMember2024-01-012024-06-300001326732us-gaap:EmployeeStockOptionMember2024-12-310001326732us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001326732us-gaap:EmployeeStockOptionMember2025-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-12-310001326732us-gaap:RestrictedStockUnitsRSUMember2025-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2025-04-012025-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2025-04-012025-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2024-04-012024-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2024-04-012024-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2025-01-012025-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2025-01-012025-06-300001326732srt:MinimumMemberus-gaap:EmployeeStockMember2024-01-012024-06-300001326732srt:MaximumMemberus-gaap:EmployeeStockMember2024-01-012024-06-300001326732us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001326732us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001326732us-gaap:EmployeeStockOptionMember2025-01-012025-06-300001326732us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001326732us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001326732us-gaap:LicenseMemberxncr:ReportableSegmentMember2025-04-012025-06-300001326732us-gaap:LicenseMemberxncr:ReportableSegmentMember2024-04-012024-06-300001326732us-gaap:LicenseMemberxncr:ReportableSegmentMember2025-01-012025-06-300001326732us-gaap:LicenseMemberxncr:ReportableSegmentMember2024-01-012024-06-300001326732xncr:MilestoneMemberxncr:ReportableSegmentMember2025-04-012025-06-300001326732xncr:MilestoneMemberxncr:ReportableSegmentMember2024-04-012024-06-300001326732xncr:MilestoneMemberxncr:ReportableSegmentMember2025-01-012025-06-300001326732xncr:MilestoneMemberxncr:ReportableSegmentMember2024-01-012024-06-300001326732us-gaap:RoyaltyMemberxncr:ReportableSegmentMember2025-04-012025-06-300001326732us-gaap:RoyaltyMemberxncr:ReportableSegmentMember2024-04-012024-06-300001326732us-gaap:RoyaltyMemberxncr:ReportableSegmentMember2025-01-012025-06-300001326732us-gaap:RoyaltyMemberxncr:ReportableSegmentMember2024-01-012024-06-300001326732xncr:ReportableSegmentMember2025-04-012025-06-300001326732xncr:ReportableSegmentMember2024-04-012024-06-300001326732xncr:ReportableSegmentMember2025-01-012025-06-300001326732xncr:ReportableSegmentMember2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb819ENPP3XCD3Member2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb819ENPP3XCD3Member2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb819ENPP3XCD3Member2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb819ENPP3XCD3Member2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb541CLDN6XCD3Member2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb541CLDN6XCD3Member2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb541CLDN6XCD3Member2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb541CLDN6XCD3Member2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb808B7H3XCD28Member2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb808B7H3XCD28Member2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb808B7H3XCD28Member2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb808B7H3XCD28Member2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb942XtendTL1AMember2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb942XtendTL1AMember2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb942XtendTL1AMember2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb942XtendTL1AMember2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:PlamotamabCD20XCD3Member2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:PlamotamabCD20XCD3Member2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:PlamotamabCD20XCD3Member2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:PlamotamabCD20XCD3Member2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb657CD19XCD3Member2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb657CD19XCD3Member2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb657CD19XCD3Member2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:XmAb657CD19XCD3Member2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:OtherProgramsIncludingResearchAndEarlyStageMember2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:OtherProgramsIncludingResearchAndEarlyStageMember2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:OtherProgramsIncludingResearchAndEarlyStageMember2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:OtherProgramsIncludingResearchAndEarlyStageMember2024-01-012024-06-300001326732xncr:ReportableSegmentMemberxncr:WindDownCostsOfTerminatedProgramsMember2025-04-012025-06-300001326732xncr:ReportableSegmentMemberxncr:WindDownCostsOfTerminatedProgramsMember2024-04-012024-06-300001326732xncr:ReportableSegmentMemberxncr:WindDownCostsOfTerminatedProgramsMember2025-01-012025-06-300001326732xncr:ReportableSegmentMemberxncr:WindDownCostsOfTerminatedProgramsMember2024-01-012024-06-300001326732xncr:EllenFeigalMember2025-04-012025-06-300001326732xncr:EllenFeigalMember2025-06-300001326732xncr:KevinGormanMember2025-04-012025-06-300001326732xncr:KevinGormanMember2025-06-300001326732xncr:KurtGustafsonMember2025-04-012025-06-300001326732xncr:KurtGustafsonMember2025-06-300001326732xncr:RichardRanieriMember2025-04-012025-06-300001326732xncr:RichardRanieriMember2025-06-30

_______________________________________________

_______________________________________________

(Exact name of registrant as specified in its charter)

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

In this report, unless otherwise stated or the context otherwise indicates, references to “Xencor,” “the Company,” “we,” “us,” “our” and similar references refer to Xencor, Inc. The Xencor logo is a registered trademark of Xencor, Inc. This report also contains registered marks, trademarks, and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology.

These forward-looking statements should, therefore, be considered in light of various important factors, including but not limited to, the following:

•the effects of inflation on our financial condition, results of operations, cash flows and performance;

•our ability to execute on our plans to research, develop and commercialize our product candidates;

•the success of our ongoing and planned clinical trials;

•the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;

•our ability to identify additional products or product candidates with significant commercial potential that are consistent with our business objectives;

•our ability to receive research funding and achieve anticipated milestones under our collaborations;

•our partners’ abilities to advance drug candidates into, and successfully complete, clinical trials;

•our ability to attract collaborators with development, regulatory, and commercialization expertise;

•our ability to protect our intellectual property position;

•the rate and degree of market acceptance and clinical utility of our products;

•costs of compliance and our failure to comply with new and existing governmental regulations;

•the capabilities and strategy of our suppliers and vendors including key manufacturers of our clinical drug supplies;

•significant competition in our industry;

•the potential loss or retirement of key members of management;

•our failure to successfully execute our growth strategy including any delays in our planned future growth;

•our failure to maintain effective internal controls, which led to the restatement of our financial statements, and the risk that we may experience additional material weaknesses; and

•our ability to accurately estimate expenses, future revenues, capital requirements and needs for additional financing.

These forward-looking statements reflect management’s current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, “Item 1A. Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all risk factors, nor can we assess the impact of all risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You are advised, however, to consult any further disclosure we make in our reports filed with the Securities and Exchange Commission.

			June 30, 2025						December 31, 2024
			(unaudited)
Assets
Current assets:
Cash and cash equivalents			$	44,442					$	40,875
Marketable debt securities			358,984						408,971
Marketable equity securities			40,438						47,929
Accounts receivable			47,554						60,849
Prepaid expenses and other current assets			21,732						18,977
Total current assets			513,150						577,601
Property and equipment, net			56,791						59,800
Patents, licenses, and other intangible assets, net			11,252						18,485
Restricted cash			286						387
Marketable debt securities - long term			260,399						256,833
Right-of-use assets			37,048						38,341
Other assets			498						498
Total assets			$	879,424					$	951,945
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable			$	18,533					$	16,759
Accrued expenses			23,884						19,217
Lease liabilities			3,380						3,009
Liabilities related to the sales of future royalties			50,286						48,447
Total current liabilities			96,083						87,432
Uncertain tax position payable			3,703						9,990
Lease liabilities, net of current portion			64,551						65,338
Liabilities related to the sales of future royalties, net of current portion			94,736						115,159
Total liabilities			259,073						277,919
Commitments and contingencies
Noncontrolling interest and stockholders’ equity
Common stock, $0.01 par value: Authorized 200,000 shares Issued and outstanding 71,297 and 70,256 shares at June 30, 2025 and December 31, 2024, respectively.			714						703
Additional paid-in capital			1,402,658						1,381,607
Accumulated other comprehensive income (loss)			258						(663)
Accumulated deficit			(783,279)						(704,036)
Total stockholders’ equity attributable to Xencor, Inc.			620,351						677,611
Noncontrolling interest			—						(3,585)
Total noncontrolling interest and stockholders’ equity			620,351						674,026
Total liabilities and stockholders’ equity			$	879,424					$	951,945

Xencor, Inc. (the “Company”) was incorporated in California in 1997 and reincorporated in Delaware in September 2004. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. The Company leverages its protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties. These candidates are advanced into clinical-stage development, where the Company is conducting Phase 1 studies across a broad portfolio of programs. Based on the results of these studies, the Company determines which programs to advance into later-stage development and potential commercialization, which to partner in order to access complementary resources, and which to discontinue.

The interim consolidated financial statements of Xencor, Inc. are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applicable to interim periods. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company’s financial position, the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated.

Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 for more complete descriptions and discussions. Operating results and cash flows for the three and six months ended June 30, 2025 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2025.

The interim consolidated financial statements included the accounts of Xencor, Inc. and Gale, a variable interest entity for which the Company was the primary beneficiary. Up through January 20, 2025, the Company owned or was exposed to less than 100% of the economics, and accordingly, the Company recorded net loss attributable to noncontrolling interests in its consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party. Effective January 20, 2025, the Company obtained 100% of the economic interests in Gale and no longer recognized a noncontrolling interest in its consolidated financial statements.

Effective April 29, 2025, Gale was merged into the Company in a transaction between entities under common control. The Company completed a common-control transfer of assets and liabilities with Gale. The assets and liabilities were recognized at historical carrying amounts; no fair value measurement was applied. This transaction did not result in a change in reporting entity and was accounted for prospectively, with no adjustments to prior periods.

The Company recorded an income tax benefit of $0.3 million and an income tax expense of $0.1 million for the three and six months ended June 30, 2025, respectively. No income tax provision was recorded for each of the three and six months ended June 30, 2024. As of June 30, 2025, the Company’s deferred income tax assets, consisting primarily of capitalized R&D under IRC Section 174, net operating loss and research and development tax credit carryforwards, have been fully offset by a valuation allowance.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, making permanent key elements of the Tax Cuts and Jobs Act, including 100% bonus depreciation, expensing of domestic research and development costs, and the limitation on business interest expense deduction. The Company is currently evaluating the impact of the new tax law on its financial condition and results of operations. However, the Company does not expect a material impact on its effective income tax rate or its net deferred federal income tax assets, as it continues to maintain a full valuation allowance.

The impact of the OBBBA will be reflected in the Company’s consolidated financial statements in the quarter ending September 30, 2025.

There have been no changes to the significant accounting policies disclosed in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

The Company does not expect any recently issued accounting standards, other than those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024, to have a material impact on its financial results.

The following table provides a summary of revenue recognized:

The following table presents a disaggregation of revenue recognized during the periods indicated:

Alexion Pharmaceuticals, Inc. (“Alexion”)

In January 2013, the Company entered into an Option and License Agreement (the “Alexion Agreement”) with Alexion. Under the terms of the Alexion Agreement, the Company granted to Alexion an exclusive research license, with limited sublicensing rights, to make and use the Company’s Xtend technology to evaluate and advance compounds. Alexion exercised its rights to one target program, ALXN1210, which is now marketed as Ultomiris®.

Under the Alexion Agreement, no further milestone payments are expected. The Company is entitled to receive royalties based on a percentage of net sales of Ultomiris sold by Alexion, its affiliates or its sublicensees, which percentage is in the low single digits. Alexion’s royalty obligations continue on a product-by-product and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country.

On November 3, 2023, the Company entered into a royalty sale agreement (the “Ultomiris Royalty Sale Agreement”) with OCM Life Sciences Portfolio LP (“OMERS”), under which OMERS acquired the rights to certain royalties associated with the existing license relating to Ultomiris.

Under the Alexion Agreement, the Company recognized non-cash royalty revenue of $16.8 million and $13.9 million during the three months ended June 30, 2025 and 2024, respectively, and $32.3 million and $26.5 million during the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, the Company recorded $17.2 million in accounts receivable based on estimated royalties due under the arrangement.

Payment of this receivable will be made directly to OMERS. See Note 6.

In June 2010, the Company entered into a Collaboration and License Agreement (the “MorphoSys Agreement”) with MorphoSys AG (“MorphoSys”). Under the MorphoSys Agreement, the Company granted MorphoSys an exclusive worldwide license to its patents and know-how to research, develop and commercialize the XmAb5574 product candidate (subsequently renamed MOR208 and tafasitamab) with the right to sublicense under certain conditions. In February 2024, Incyte assumed all of MorphoSys’ right, title and interest in the MorphoSys Agreement and acquired exclusive global development and commercialization rights to tafasitamab. If certain developmental, regulatory and sales milestones are achieved, the Company is eligible to receive future milestone payments and royalties from Incyte.

The United States Food and Drug Administration (“FDA”) accepted Incyte’s submission of a supplemental biologics license application in February 2025, triggering a $12.5 million milestone payment to the Company, which was paid in the second quarter of 2025. The FDA approved the application in June 2025, triggering a $25.0 million milestone payment to the Company, which was paid in the third quarter of 2025.

Under the MorphoSys Agreement, the Company is eligible to receive up to $98.0 million in developmental, regulatory and sales milestones, as well as royalties on net sales, subject to the terms and conditions of the agreement.

On November 3, 2023, the Company entered into a royalty sale agreement (the “Monjuvi Royalty Sale Agreement”) with OMERS, under which OMERS acquired the rights to certain royalties associated with the existing license relating to Incyte. The $37.5 million of milestone payments the Company received in 2025 is not subject to the Monjuvi Royalty Sale Agreement.

Under the MorphoSys Agreement, the Company recognized non-cash royalty revenue of $1.8 million and $1.5 million of non-cash royalty revenue during the three months ended June 30, 2025 and 2024, respectively, and $4.5 million and $4.4 million during the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, the Company recorded $3.2 million in accounts receivable based on estimated royalties due under the arrangement. Payment of this receivable will be made directly to OMERS. See Note 6.

On December 22, 2023, the Company entered into a Technology License Agreement with Mabgeek. On June 21, 2024, the parties entered into Amendment No. 1 to the Technology License Agreement (as amended, the “Mabgeek Agreement”). Under the Mabgeek Agreement, the Company received an upfront payment of $1.5 million, which was recognized as revenue, and is eligible to receive royalties in the low single digits on net sales of approved products.

The Company evaluated the Mabgeek Agreement and determined that it contains a single performance obligation—access to a non-exclusive license to certain Company patents, which was transferred to Mabgeek in June 2024.

Under the Mabgeek Agreement, the Company is eligible to receive up to $11.9 million in developmental, regulatory and sales milestones, as well as royalties on net sales, subject to the terms and conditions of the agreement.

Vega Therapeutics, Inc. (“Vega”)

In October 2021, the Company entered into a Technology License Agreement (the “Vega Agreement”) with Vega, granting Vega a non-exclusive license to its Xtend Fc technology. In March 2024, Vega initiated a Phase 1 study, triggering a $0.5 million milestone payment, which was recognized as revenue.

Under the Vega Agreement, the Company is eligible to receive up to $30.0 million in developmental, regulatory and sales milestones, as well as royalties on net sales, subject to the terms and conditions of the agreement.

Vir Biotechnology, Inc. (“Vir Bio”)

In 2019, the Company entered into a Patent License Agreement (the “Vir Bio Agreement”) with Vir Bio, granting a non-exclusive license to its Xtend technology for up to two targets. In March 2025, Vir Bio initiated a Phase 3 study for tobevibart, triggering a $2.0 million milestone payment to the Company, which was paid in the second quarter of 2025.

In March 2020, the Company entered into a second Patent License Agreement (the “Second Vir Bio Agreement”) with Vir Bio, granting a non-exclusive license to its Xtend technology to extend the half-life of novel antibodies Vir Bio developed as potential treatments for patients with COVID-19, including sotrovimab. Under the terms of the Second Vir Bio Agreement, Vir Bio is responsible for all research, development, regulatory and commercial activities for the antibodies, and the Company is eligible to receive royalties on the net sales of approved products in the mid-single digit percentage range.

Vir Bio and its marketing partner, GSK, began recording sales for sotrovimab beginning in June 2021.

The Company recognized nominal amounts of royalty revenue for the three and six months ended June 30, 2025 and 2024. Under the Vir Bio Agreement, the Company is eligible to receive up to $152.0 million in developmental, regulatory and sales milestones, as well as royalties on net sales, subject to the terms and conditions of the agreement.

In May 2024, the Company entered into a Patent License Agreement with a third-party licensee. The Company satisfied its performance obligation under the agreement, triggering a $7.0 million payment to the Company, which was paid in the third quarter of 2024. There is no further obligation under this agreement.

The Company’s marketable debt securities consisted of the following:

The following table summarizes the contract maturities of the Company’s marketable debt securities as of June 30, 2025:

The Company did not record any impairment losses on its marketable debt securities during the three and six months ended June 30, 2025 and 2024.

The Company’s marketable equity securities consisted of the following:

During the second quarter of 2025, the Company sold 1,717,158 shares of INmune Bio, Inc., generating $13.4 million in proceeds. The remaining 168,375 shares were sold in July 2025.

Net realized and unrealized gains (losses) on marketable equity securities, recognized in other income (expense) in the consolidated statements of operations, were as follows:

The Company did not record any impairment losses on its marketable equity securities during the three and six months ended June 30, 2025. There was an impairment charge of $20.4 million recorded for the six months ended June 30, 2024 in connection with equity securities without a readily determinable fair value.

4. Fair Value of Measurements

The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company’s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 1, Summary of Significant Accounting Policies of Notes to Consolidated Financial Statements of Part II, “Item 8. Consolidated Financial Statements and Supplementary Data” of its Annual Report on Form 10-K for the year ended December 31, 2024.

The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. As of June 30, 2025 and December 31, 2024, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:

The following table summarizes the Company’s major classes of property and equipment:

Depreciation and amortization expense for property and equipment for the three months ended June 30, 2025 and 2024 was $2.4 million and $2.7 million, respectively. Depreciation and amortization expense for property and equipment for the six months ended June 30, 2025 and 2024 was $4.8 million and $5.4 million, respectively.

The following table summarizes the Company’s patents, licenses, and other intangible assets:

Patents, licenses and other intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Amortization expense was $0.3 million for each of the three months ended June 30, 2025 and 2024. Amortization expense was $0.5 million and $0.6 million for the six months ended June 30, 2025 and 2024, respectively. None of these assets with definite useful lives are anticipated to have a residual value.

Patents, licenses and other intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. The Company recorded the asset impairment charges of $1.9 million and $6.7 million during the three and six months ended June 30, 2025, respectively, related to its decision to pause further development of certain programs and prioritize resources toward advancing other pipeline programs. As a result, associated patents related to the paused programs were impaired. No impairment charges were recorded for each of the three and six months ended June 30, 2024.

The following table presents the estimated future amortization expense related to definite-lived assets as of June 30, 2025:

Accrued expenses consist of the following:

On November 3, 2023, the Company and OMERS entered into the Ultomiris Royalty Sale Agreement. Pursuant to the Ultomiris Royalty Sale Agreement, OMERS acquired the rights to a portion of royalties and milestones earned after July 1, 2023 associated with the existing license relating to Ultomiris® (ravulizumab-cwvz) in exchange for an upfront payment of $192.5 million. Pursuant to the Ultomiris Royalty Sale Agreement and subject to the Company’s existing license with Alexion, OMERS acquired the right to receive: (i) 100% of royalties payable on past and future sales related to Ultomiris that occur from July 1, 2023 through December 31, 2025; (ii) up to $35.0 million annually in royalties on future sales related to Ultomiris that occur from January 1, 2026 through December 31, 2028, with any royalties in excess of $35.0 million reverting to the Company; (iii) up to $12.0 million annually in royalties on future sales related to Ultomiris that occur from and after January 1, 2029, with any royalties in excess of $12.0 million reverting to the Company; and (iv) $18.0 million of a certain future sales based milestone payment pursuant to the existing license with Alexion, which was paid in the fourth quarter of 2023.

On November 3, 2023, the Company and OMERS entered into the Monjuvi Royalty Sale Agreement. Pursuant to the Monjuvi Royalty Sale Agreement, OMERS acquired the rights to a portion of royalties earned after July 1, 2023 associated with the existing license relating to Monjuvi®/Minjuvi® (tafasitamab-cxix) in exchange for an upfront payment of $22.5 million. Pursuant to the Monjuvi Royalty Sale Agreement and subject to the Company’s existing license with Incyte, OMERS acquired the right to receive up to $29.3 million in royalties earned after July 1, 2023 related to sales of Monjuvi/Minjuvi, with any royalties in excess of $29.3 million paid to OMERS reverting to the Company.

The Company has evaluated the terms of both Ultomiris and Monjuvi Royalty Sale Agreements and concluded, in accordance with the relevant accounting guidance, that the Company accounted for both transactions as debt and the proceeds recorded as liabilities related to the sale of future royalties on its consolidated balance sheets.

The Company records the obligations at their carrying value using the effective interest method. In order to amortize the liabilities related to the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions such as future sales forecasts and other significant events. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June 30, 2025, the estimated effective interest rates were 23.1% and 16.6% for Ultomiris and Monjuvi Royalty Sale Agreements, respectively.

The following table presents the activities with respect to the liabilities related to the sales of future royalties:

From time to time, the Company may be subject to claims and legal proceedings arising in the ordinary course of business. The Company evaluates each matter and assesses its potential financial exposure. If the potential loss from a legal proceeding is considered probable and the amount can be reasonably estimated, the Company records an accrual for the estimated loss. Because the outcome of legal proceedings is inherently uncertain, significant judgment is required in assessing the likelihood of a loss and whether the amount is reasonably estimable. The Company’s assessments and any recorded accruals are based on information available at the time of evaluation. As additional information becomes available, the Company re-evaluates its estimates and may adjust recorded liabilities accordingly.

The Company is currently a party to an action initiated by Merus N.V. (“Merus”) in the District of Delaware alleging that the Company’s manufacture, use, offer for sale, sale and/or importation of common light chain antibodies and heterodimeric antibodies infringes certain claims of three Merus patents. Merus filed its complaint against the Company on August 5, 2024. Merus asserted claims of U.S. Patent Nos. 9,944,695, 9,358,286 and 11,926,859 (collectively, the “Asserted Patents”). Merus seeks a judgment of patent infringement, an order enjoining the Company from infringing the Asserted Patents, a damages award (together with interest), a declaration of willful infringement, and a finding that this case is exceptional. On October 10, 2024, the Company filed a motion to dismiss the Merus complaint with prejudice under Rule 12(b)(6), in which the Company argued that all of the activities accused of infringement are covered by the 35 U.S.C.§ 271(e)(1) safe harbor. Merus filed its response to the Company’s motion on October 31, 2024, and the Company replied to Merus’ response on November 14, 2024. Both Merus and the Company requested a hearing for the motion to dismiss. On February 11, 2025, the Company filed for inter partes review of Merus’ U.S. Patent Nos. 9,358,286 and 11,926,859 before the U.S. Patent and Trademark Appeal Board seeking a finding that certain claims of those patents are unpatentable. The Company believes it has strong defenses to Merus’ claims, including defenses of invalidity and/or non-infringement, but there is no guarantee that the Company will prevail.

The Company is party to certain license agreements that obligate it to make future payments to third parties, which may include sublicense fees, royalties and milestone payments contingent upon the achievement of specified development and commercialization events. Because the occurrence, timing and amounts of these potential payments are not currently probable or reasonably estimable, they have not been recorded on the Company’s consolidated balance sheets as of June 30, 2025 and December 31, 2024.

In addition, the Company has entered into agreements with various third-party vendors for research, development and manufacturing services. These agreements generally provide for future payments contingent upon the vendors’ delivery of goods or performance of services. Such commitments are not recorded until the related goods or services are received.

The following table summarizes the Company’s shares of common stock and preferred stock:

On February 27, 2023, the Company filed an automatic universal shelf registration statement on Form S-3 (File No. 333-270030) as a well-known seasoned issuer as defined in Rule 405 under the Securities Act of 1933, as amended, which became effective upon filing (the "Shelf Registration Statement"). The Shelf Registration Statement allows the Company to offer an indeterminate amount of securities, including equity securities, debt securities, warrants, rights, units and depositary shares, from time to time as described in the Shelf Registration Statement.

The specific terms of any offering under the Shelf Registration Statement will be established at the time of such offering. The Shelf Registration Statement will expire on February 27, 2026.

On February 27, 2023, the Company entered into a sales agreement (the “Sales Agreement”) with SVB Securities LLC (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent (the “ATM Offering”), shares of its common stock having an aggregate offering price of up to $200.0 million (the “ATM Shares”). Any ATM Shares offered and sold in the ATM Offering will be issued pursuant to the Company’s Shelf Registration Statement and the prospectus supplement filed pursuant to Rule 424(b) relating to the ATM Offering, dated February 27, 2023. As of June 30, 2025, no shares have been issued under the Sales Agreement.

On September 12, 2024, the Company completed an underwritten public offering pursuant to the Company’s Shelf Registration Statement. In the offering, the Company sold pre-funded warrants to purchase up to 3,088,888 shares of common stock at a purchase price of $17.99 per pre-funded warrant, for an aggregate value of approximately $55.6 million. The outstanding pre-funded warrants are exercisable at any time and do not have an expiration date.

Monrovia, California: The Company leases office and laboratory space in Monrovia, California, which lease expires in December 2025. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew, and therefore, it is not included in right-of-use assets and liabilities as of June 30, 2025.

Pasadena, California: In June 2021, the Company entered into a lease agreement for laboratory and office space in Pasadena, California, with a lease term through July 2035 and no renewal option. The lease includes two phases: Phase 1 commenced on August 1, 2022, and Phase 2 commenced on December 1, 2022.

The lease provides tenant improvement allowances of up to $17.0 million for Phase 1 and $3.3 million for Phase 2. In August 2022, the lease was amended to provide an additional $5.0 million in Phase 1 improvement allowance in exchange for an increase in rent.

San Diego, California: In August 2023, the Company entered into a sublease agreement for office space in San Diego, California, with a lease term from September 2023 through December 2027. As part of the sublease, the Company issued a $0.4 million letter of credit to the landlord, secured by a cash collateral account classified as restricted cash on the consolidated balance sheets. The amount of the letter of credit will decrease over the lease term.

The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants. The components of lease assets and liabilities along with their classification on the Company’s consolidated balance sheets were as follows:

The following table presents maturities of operating lease liabilities on an undiscounted basis as of June 30, 2025:

The following table presents lease costs, supplemental cash flow and other information:

In June 2023, the Company’s Board of Directors (the “Board”) and stockholders approved the 2023 Equity Incentive Plan (the “2023 Plan”), which became effective on June 14, 2023, and replaced the 2013 Equity Incentive Plan (the “2013 Plan”). No additional awards may be granted under the 2013 Plan.

The 2023 Plan reserves 3,000,000 shares of common stock, plus any remaining shares available under the 2013 Plan as of the effective date. In addition, shares subject to outstanding awards under the 2013 Plan that expire, are forfeited, or otherwise terminate without being issued after June 14, 2023, will be added to the 2023 Plan share reserve. The 2023 Plan does not include an automatic annual share increase (an evergreen provision). On June 12, 2025, the Company’s stockholders approved the amendment and restatement of the 2023 Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares. As of June 30, 2025, the total number of shares of common stock reserved for issuance under the 2023 Plan is 20,405,637.

In addition, the Company’s Board and stockholders approved the Employee Stock Purchase Plan (the “ESPP”), which became effective on December 5, 2013. As of June 30, 2025, the total number of shares of common stock available for issuance under the ESPP is 865,198.

The following table presents a summary of awards outstanding:

The following table summarizes stock-based compensation expenses included in operating expenses:

The following table presents a summary of the stock option activity for the six months ended June 30, 2025: